New immune cell attack shows promise against tough cancers
NCT ID NCT06562647
First seen Feb 16, 2026 · Last updated May 05, 2026 · Updated 10 times
Summary
This early study tests a new treatment called SY001 for people with advanced ovarian or pancreatic cancer that has not responded to at least one prior therapy. SY001 uses specially engineered immune cells (CAR-macrophages) to target a protein called mesothelin found on cancer cells. The main goal is to find a safe dose and check for side effects in a small group of 2 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Linyi Cancer Hospital
NOT_YET_RECRUITINGLinyi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.